Business Description
Inhibikase Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US45719W2052
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 44.61 | |||||
Equity-to-Asset | 0.58 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -22 | |||||
3-Year EPS without NRI Growth Rate | -19.3 | |||||
3-Year FCF Growth Rate | -60.2 | |||||
3-Year Book Growth Rate | -32.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 24.18 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
6-1 Month Momentum % | -21.9 | |||||
12-1 Month Momentum % | -41.21 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.32 | |||||
Quick Ratio | 2.32 | |||||
Cash Ratio | 2.14 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -54.6 | |||||
Shareholder Yield % | -40.07 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -160.31 | |||||
ROA % | -123.16 | |||||
ROIC % | -1987.24 | |||||
3-Year ROIIC % | 1343.08 | |||||
ROC (Joel Greenblatt) % | -6447.08 | |||||
ROCE % | -164.47 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.66 | |||||
Price-to-Tangible-Book | 1.65 | |||||
EV-to-EBIT | -0.05 | |||||
EV-to-EBITDA | -0.05 | |||||
EV-to-Forward-Revenue | 1358.04 | |||||
EV-to-FCF | -0.06 | |||||
Price-to-Net-Current-Asset-Value | 1.72 | |||||
Price-to-Net-Cash | 2.02 | |||||
Earnings Yield (Greenblatt) % | -2000 | |||||
FCF Yield % | -188.57 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Inhibikase Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | 0 | ||
Beta | 0 | ||
Volatility % | 99.79 | ||
14-Day RSI | 0 | ||
14-Day ATR (€) | 0 | ||
20-Day SMA (€) | 0 | ||
12-1 Month Momentum % | -41.21 | ||
52-Week Range (€) | 2.555999 - 5.609999 | ||
Shares Outstanding (Mil) | 5.35 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Inhibikase Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Inhibikase Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Inhibikase Therapeutics Inc Frequently Asked Questions
What is Inhibikase Therapeutics Inc(FRA:IQT0)'s stock price today?
When is next earnings date of Inhibikase Therapeutics Inc(FRA:IQT0)?
Does Inhibikase Therapeutics Inc(FRA:IQT0) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |